As per the 2023 United States National Survey on Drug Use and Health (NSDUH), 48.5 million Americans (aged 12 and above) were affected by substance use disorder in the past year, accounting for 16.7% of the population. Genetics, including the influence of environmental factors on gene expression, contribute to around 40%-60% of an individual’s risk of drug addiction. With a substantial proportion of the population impacted by substance use disorders, the demand for effective medications for combating addiction is increasing.
Major companies involved in the substance (drug) abuse pipeline drugs market include Tonix Pharmaceuticals, Inc. and Tempero Bio, Inc., among others.
Leading drugs currently under the pipeline include TMP-301 and probenecid, among others.
Increased investment in research and development for innovative addiction treatments and robust regulatory support are anticipated to positively influence the drug pipeline landscape.
The Substance (Drug) Abuse Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into substance (drug) abuse drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for substance (drug) abuse. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The substance (drug) abuse pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from substance (drug) abuse.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to substance (drug) abuse.
Substance (drug) abuse includes a pattern of excessive use of psychoactive drugs that can lead to physical, emotional, or social harm. Drug abuse involves both psychological and physical dependence on drugs such as pain medications or alcohol. Genetic predisposition and environmental factors can increase a person’s risk of addiction. Additionally, people with mental health disorders and teenagers are more prone to drug use and addiction compared to other populations.
Medication along with some type of behavioral therapy or counseling is considered the first line of treatment for people suffering from opioid addiction. Common medications include methadone, buprenorphine, extended-release naltrexone, and lofexidine which help in treating opioid drug addiction and withdrawal. With increasing funding and support for addiction research and treatment programs from governmental and non-governmental organizations, the substance (drug) abuse pipeline is anticipated to witness a steady expansion in the coming years.
This section of the report covers the analysis of substance (drug) abuse drugs based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I and II cover a major share of the total clinical trials for substance (drug) abuse.
The drug molecule categories covered under the substance (drug) abuse pipeline analysis include small molecule, biologics, peptide, monoclonal antibody, and others. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for substance (drug) abuse.
The EMR report for the substance (drug) abuse drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in substance (drug) abuse clinical trials:
Major drugs currently in the drug pipeline are as follows:
Sponsored by Tempero Bio, Inc., the objective of this participant-blinded, placebo-controlled Phase II study is to assess the preliminary efficacy, tolerability, and safety of TMP-301 in around 100 adult patients with alcohol use disorder (AUD).
This Phase II clinical trial is aimed at investigating the use of the drug probenecid in alleviating the symptoms of opioid withdrawal in people affected by dependence on opioid medications. The interventional study has enrolled an estimated 40 subjects and is expected to be completed by December 2025.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Substance (Drug) Abuse Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for substance (drug) abuse. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within substance (drug) abuse pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share